Article

Does early olaparib administration improve prognosis in patients with HER2-negative metastatic breast cancer and BRCA1 and/or BRCA2 pathogenic variants?: Finding from four cases

2022-07-04

Abstract excerpt

We herein describe our experience of four patients who had been diagnosed as metastatic breast cancer with BRCA 1/2 pathogenic variants. Prior anthracycline and/or taxane-based therapies needed before administration of PARP inhibitors might be still controversial in terms of patients benefit.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2882b252-75db-547a-aebc-c2814a41ec32
DOI: 10.22541/au.165692195.50180823/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Does early olaparib administration improve prognosis in patients with HER2-negative metastatic breast cancer and BRCA1 and/or BRCA2 pathogenic variants?: Finding from four casesDOI 10.22541/au.165692195.50180823/v1Read

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 MutationSemantic proximity Read

BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.Semantic proximity Read

Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast CancerSemantic proximity Read

FDA approves olaparib for germline BRCA-mutated metastatic breast cancerSemantic proximity Read

Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological TherapiesSemantic proximity Read

First PARP Inhibitor Ok'd for Breast CancerSemantic proximity Read

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationSemantic proximity Read

Biological Therapies Beyond PARP-Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 MutationsSemantic proximity Read

Olaparib for Metastatic Germline BRCA-Mutated Breast CancerSemantic proximity Read

Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.Semantic proximity Read

[Olaparib Could Be Re-Administered after Chemotherapy].Semantic proximity Read

Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.Semantic proximity Read